(Q38469030)

3 September 2017

Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. (English)

1 reference

3 September 2017

0 references

Mi H Park

1

1 reference

3 September 2017

Min J Song

2

1 reference

3 September 2017

Min-Chul Cho

3

1 reference

3 September 2017

Dong C Moon

4

1 reference

3 September 2017

Do Y Yoon

5

1 reference

3 September 2017

Sang B Han

6

1 reference

3 September 2017

Jin T Hong

7

1 reference

3 September 2017

1 January 2012

1 reference

3 September 2017

1 reference

3 September 2017

135

1 reference

3 September 2017

1

1 reference

3 September 2017

63-72

1 reference

Natural killer cells, viruses and cancer

3 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

The biology of human natural killer-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

New aspects of natural-killer-cell surveillance and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Activation and function of natural killer cell responses during viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

A contribution of mouse dendritic cell-derived IL-2 for NK cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Death receptor 3 (DR3) gene duplication in a chromosome region 1p36.3: gene duplication is more prevalent in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Identification of a ligand for the death-domain-containing receptor Apo3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Death receptors: signaling and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Cell surface Death Receptor signaling in normal and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Nature's TRAIL--on a path to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Molecular characterization of defective antigen processing in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Interleukin-32: a cytokine and inducer of TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

IL-32-dependent effects of IL-1beta on endothelial cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

IL-32, a novel cytokine with a possible role in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Natural killer cells and nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Defective NK cell activity and Th1 response in IL-18-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3246653

Interleukin-2 in the treatment of renal cancer

16 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3246653

Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.

16 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3246653

A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.

16 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3246653

IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor.

16 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3246653

Biology and clinical relevance of human natural killer cells

16 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3246653

Identification of a novel gene expressed in activated natural killer cells and T cells

16 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3246653

Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes

16 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2011.03513.X

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

21 January 2018

1 reference

12 December 2020

Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer

1 reference

12 December 2020

MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma

1 reference

12 December 2020

Interleukin-18: a novel cytokine that augments both innate and acquired immunity

1 reference

12 December 2020

The Interactions of Multiple Cytokines Control NK Cell Maturation

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer

1 reference

12 December 2020

IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells

1 reference

12 December 2020

10.1111/J.1365-2567.2011.03513.X

Identifiers

DOI

1 reference

3 September 2017

0 references

1 reference